| 杨 春,殷宇岗,徐 恒,郭 华,李 瑶,吕 磊.冠心病患者血清CXCR3、CXCL5、CXCL12水平与冠脉病变程度和预后的关系研究[J].现代生物医学进展英文版,2021,(24):4713-4718. |
| 冠心病患者血清CXCR3、CXCL5、CXCL12水平与冠脉病变程度和预后的关系研究 |
| Study on the Relationship between Serum CXCR3, CXCL5, CXCL12 Levels and the Severity of Coronary Artery Disease and Prognosis in Patients with Coronary Heart Disease |
| Received:April 17, 2021 Revised:May 11, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.24.023 |
| 中文关键词: 冠心病 Gensini积分 主要心血管不良事件 CXCR3 CXCL5 CXCL5 |
| 英文关键词: Coronary heart disease Gensini integral Major adverse cardiovascular events CXCR3 CXCL5 CXCL5 |
| 基金项目:军委后勤保障卫生局保健专项基金（18BJZ13） |
|
| Hits: 741 |
| Download times: 476 |
| 中文摘要: |
| 摘要 目的：探讨冠心病（CHD）患者血清CXC亚族趋化因子受体（CXCR）3、C-X-C趋化因子配体（CXCL）5、CXCL12水平与冠状动脉病变程度和预后的关系。方法：选择2018年2月至2020年2月我院心脏内科收治的189例CHD患者（CHD组），根据Gensini积分将患者分为轻度病变组（≤20分，62例）、中度病变组（21～40分，84例）和重度病变组（＞40分，43例），根据随访期间是否发生主要心血管不良事件（MACE）将患者分为MACE组（45例）和无MACE组（144例），另选择102例同期于我院进行健康体检志愿者为对照组。检测血清CXCR3、CXCL5、CXCL12水平，分析其与CHD患者随访期间发生MACE的关系。结果：CHD组血清CXCR3、CXCL5、CXCL12水平高于对照组（P＜0.05），重度病变组血清CXCR3、CXCL5、CXCL12水平高于中度病变组和轻度病变组（P＜0.05），中度病变组血清CXCR3、CXCL5、CXCL12水平高于轻度病变组（P＜0.05）。单因素分析结果显示，左心室射血分数（LVEF）、高血压、糖尿病、高脂血症、血糖、冠脉病变支数、冠脉病变长度、Gensini积分、血清C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、CXCR3、CXCL5、CXCL12水平与CHD患者随访期间发生MACE有关（P<0.05）。多因素Logistic回归分析显示，冠脉病变支数、高血压、CXCR3、CXCL5、CXCL12是CHD患者随访期间发生MACE的影响因素（P＜0.05）。结论：CHD患者血清CXCR3、CXCL5、CXCL12水平均增高，且与冠状动脉病变加重和MACE发生有关，检测血清CXCR3、CXCL5、CXCL12有助于评估CHD患者的病情和预后。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate relationship between serum CXC subfamily chemokine receptor 3 (CXCR3),C-X-C chemokine ligand (CXCL) 5, CXCL12 levels and the severity of coronary artery disease and prognosis in patients with coronary heart disease (CHD). Methods: A total of 189 patients with CHD (CHD group) who were admitted to the department of cardiology of our hospital from February 2018 to February 2020 were selected. According to Gensini integral, the patients were divided into mild lesion group (≤20 scores, 62 cases), moderate lesion group(21～40 scores, 84 cases) and severe lesion group (> 40 scores, 43 cases). According to the occurrence of major adverse cardiovascular events (MACE) during the follow-up period, the patients were divided into MACE group (45 cases) and non MACE group (144 cases), another 102 volunteers who underwent physical examination in our hospital at the same time were selected as the control group. Serum CXCR3, CXCL5, CXCL12 levels were detected, and the relationship between they and the occurrence of MACE in patients with CHD during follow-up. Results: The serum CXCR3, CXCL5 and CXCL12 levels in CHD group were higher than those in control group (P<0.05), and the serum CXCR3, CXCL5 and CXCL12 levels in severe lesion group were higher than those in moderate lesion group and mild lesion group (P<0.05). The serum CXCR3, CXCL5 and CXCL12 levels in moderate lesion group were higher than those in mild lesion group(P<0.05). The results of single factor analysis showed that left ventricular ejection fraction(LVEF), hypertension, diabetes, hyperlipemia, blood sugar, number of coronary artery lesions, length of coronary artery lesions, Gensini integral, serum C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), CXCR3, CXCL5, CXCL12 levels were correlated with the occurrence of MACE in patients with CHD during follow-up(P<0.05). Multivariate Logistic regression analysis showed that the number of coronary artery lesions, hypertension, CXCR3, CXCL5 and CXCL12 were the influential factors for the occurrence of MACE in patients with CHD during follow-up(P<0.05). Conclusion: The serum CXCR3, CXCL5 and CXCL12 levels in patients with CHD are increased, and they are related to the exacerbation of coronary artery disease and the occurrence of MACE. The detection of serum CXCR3, CXCL5 and CXCL12 is helpful to evaluate the condition and prognosis of CHD patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
